Institute for Medical Research (NIMR).
He worked with and was scientifically stimulated by various scientists -several of whom later won Nobel prizes in Chemistry or Physiology and Medicine. Working with them he learned technical expertise in peptide chemistry, the philosophy of research, and a systematic approach to scientific investigations. In 1952, he moved to Canada studying at McGill University, where he learned endocrinology at the Allan Memorial Institute. Thus, his academically formative years were spent in Canada. At McGill, they studied corticotropin (ACTH) and adrenal cortical steroids related to stress. That period heralded his beginning interest in the relationship between brain function and endocrine activity. If we look a little back into his history, we will find out the reason both for his personality and his Nobel Prize achievement.
He was born in Poland and spent the war years in Romania, Italy, and France, eventually joining his father in England. He completed high school in Scotland and then studied chemistry in London. As a child, he was exposed to many languages and became fluent in Latin, Romanian, Italian, French, Yiddish, and German. This facility allowed him to acquire later Spanish and Portuguese. 
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Prize of the American Thyroid Association. Thus, TRH became the first hypothalamic hormone to be structurally determined and synthesized. This settled forever the skepticism surrounding the interaction of hypothalamus and pituitary. In 1965, Dr. Carlos Gual from Mexico City invited him to carry out clinical testing of hypothalamic hormones there. They demonstrated that preparations of natural TRH are active in humans. They then redoubled efforts on the structure and synthesis of LHRH. Subsequently, Drs. Gual, Kastin and Schally established that porcine LHRH unequivocally released LH and FSH in men and women. This dispelled their fears of a species specificity that had been found for growth hormone (GH). The realization that LHRH might be clinically useful encouraged them to continue the agonizing effort involved in its purification.
Although he considered himself a neuroendocrinologist, not a biochemist, he personally did the isolations, as the effort required to obtain pure material from hypothalamic extract was so discouragingly enormous that only a person such as himself, with unshakable faith in hypothalamic hormones, would endure the many laborious steps of purification. He isolated a small amount (800 µg) of LHRH from 160 000 pig brains, proved it to be a peptide, and passed it on to their structural chemists, Drs. H Matsuo and Y Baba. They were able to determine the complete structure of LHRH from this tiny amount. Thus, they won the race to solve the structure of LHRH. After confirming the structure of LHRH by synthesis, Dr. Schally presented it at the Endocrine Society meeting in San Francisco in 1971. It was one of the high points in his life to be able to report, for the first time, the solution to this paramount and supremely complex problem which had preoccupied him and the other experimental endocrinologists for so many years. In summary, Dr. Schally has improved the treatment methods of hormone-dependent prostate cancer as pioneered by C Huggins. The hormonal therapies that he developed or proposed are based on the peptide analogs of hypothalamic and other hormones that he discovered and synthetized. These discoveries have led to many practical applications. Currently, he continues working on other applications of his discoveries to oncology, and particularly in urologic oncology. Recently The Canadian Journal of Urology in the section of Legends in Urology published his autobiography where I obtained most of this information. 
